WENDALL WIERENGA - 14 May 2025 Form 4 Insider Report for CYTOKINETICS INC (CYTK)

Role
Director
Signature
/s/ John O. Faurescu, attorney-in-fact for Dr. Wierenga
Issuer symbol
CYTK
Transactions as of
14 May 2025
Net transactions value
$0
Form type
4
Filing time
14 May 2025, 19:25:35 UTC
Previous filing
21 Apr 2025
Next filing
13 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
WIERENGA WENDALL Director 350 OYSTER POINT BLVD, SOUTH SAN FRANCISCO /s/ John O. Faurescu, attorney-in-fact for Dr. Wierenga 14 May 2025 0001235945

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYTK Common Stock Award $0 +7,333 +30% $0.000000 32,181 14 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYTK Non-Qualified Stock Option (Right to Buy) Award $0 +10,880 $0.000000 10,880 14 May 2025 Common Stock 10,880 $30.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Comprised of restricted stock units ("RSUs") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting.
F2 Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors.